Market Overview:
The global pneumonia testing market reached a value of US$ XX Million in 2021. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Pneumonia is an infection in the lower respiratory tract caused by bacteria, viruses and fungi. It spreads via the inhalation of airborne droplets from the sneeze or cough of an infected person. It leads to inflammation in the air sacs of the lungs and shortness of breath. It also reduces appetite and causes mild fever, dry cough, headaches, fatigue, chills and chest pain. It is diagnosed through pneumonia testing, which includes a physical examination, medical history review, chest X-ray, blood culture, pulse oximetry, sputum culture, bronchoscopy, and fluid sample.
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Pneumonia Testing Market Trends:
At present, there is a rise in the utilization of point of care (POC) testing to detect pneumonia on account of its higher efficiency and rapid and accurate test results. This, along with the burgeoning healthcare industry, represents one of the key factors driving the market. Moreover, the introduction of immunochromatographic, pneumococcal urinary antigen (UAT) and advanced nucleic acid detection tests is propelling the growth of the market. In addition, the growing awareness among individuals about the benefits of early diagnosis is augmenting the number of pneumonia testing across the globe. This, coupled with the rising healthcare expenditure by governments of several countries, is contributing to the growth of the market. Besides this, there is an increase in the adoption of enzyme-linked immunosorbent assay (ELISA) to detect pneumonia as it is highly sensitive and easier to carry out. Other growth-inducing factors are the growing geriatric population and rising prevalence of pneumonia among children around the world. Furthermore, key market players are focusing on new product launches and approvals which is projected to bolster the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global pneumonia testing market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, method, technology and end user.
Breakup by Type:
Breakup by Method:
- Immunodiagnostics
- Molecular Diagnostics
- Point of Care Testing
Breakup by Technology:
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- Enzyme-linked Immunosorbent Assay
- Immunofluorescence
- Western Blot
- Polymerase Chain Reaction
- Immunohistochemistry
- Others
Breakup by End User:
- Hospitals
- Diagnostic Laboratories
- Homecare
- Others
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc, Curetis GmbH (OpGen), DiaSorin S.p.A., Hologic Inc, Meridian Bioscience Inc, Quest Diagnostics Incorporated, Quidel Corporation, Roche Holding AG, and Thermo Fisher Scientific Inc.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2021 |
Historical Period |
2016-2021 |
Forecast Period |
2022-2027 |
Units |
US$ Million |
Segment Coverage |
Type, Method, Technology, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc, Curetis GmbH (OpGen), DiaSorin S.p.A., Hologic Inc, Meridian Bioscience Inc, Quest Diagnostics Incorporated, Quidel Corporation, Roche Holding AG, and Thermo Fisher Scientific Inc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global pneumonia testing market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global pneumonia testing market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the method?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global pneumonia testing market and who are the key players?
- What is the degree of competition in the industry?